Difference between revisions of "NF-kappa-B inhibitor alpha"
m |
|||
| (6 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
| − | |||
| − | |||
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 8: | Line 6: | ||
|- | |- | ||
| Synonyms | | Synonyms | ||
| − | | | + | | I-kappa-B-alpha |
| − | I-kappa-B-alpha | ||
|- | |- | ||
| Determination type | | Determination type | ||
| Line 30: | Line 27: | ||
|- | |- | ||
| Substrate sequence | | Substrate sequence | ||
| − | | | + | | PRDGL''KK''ERLLD |
| + | LHSIL''K''ATNYN | ||
| + | |||
| + | PSTRI''QQ''QLGQL | ||
| + | |||
| + | DCVFGG''Q''RLTL | ||
|- | |- | ||
| Structure | | Structure | ||
| − | | [http://www.rcsb.org/pdb/explore/explore.do?structureId= | + | | [http://www.rcsb.org/pdb/explore/explore.do?structureId=1IKN 1IKN] |
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
| Line 47: | Line 49: | ||
| | | | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
Latest revision as of 11:49, 10 March 2015
| NF-kappa-B inhibitor alpha | |
|---|---|
| Substrate peptide name | NF-kappa-B inhibitor alpha |
| Synonyms | I-kappa-B-alpha |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cytosol |
| Swissprot ID | P25963 |
| Reactive glutamines | Q266, Q267, Q313 |
| Reactive lysines | K21, K22, K177 |
| Substrate sequence | PRDGLKKERLLD
LHSILKATNYN PSTRIQQQLGQL DCVFGGQRLTL |
| Structure | 1IKN |
| Surface accessibility | ASAView pdf |
| Disorder prediction | IUPred |
| Reference | PMID:16987813 |
| Notes | |
